CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
POST Triheptanoindrug
Likely dose
POST Triheptanoin 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679235
NCT02679235Phase 2Completed
CompareCT.gov

Brain Energy and Aging With Triheptanoin: The BEAT7 Study

Université de Sherbrooke·interventional·Posted Feb 10, 2016·Updated Jul 23, 2020

In Brief

A Phase 2 clinical trial evaluating POST Triheptanoin for Frontal Lobe Hypometabolism. Completed, enrolled 15 participants across 1 site.

Detailed Summary

BEAT7-001 is a single group study (supplementation). Using a multi-modal brain imaging portfolio, this study will assess whether brain energy metabolism (glucose and ketones), structure or functional connectivity change in older people with frontal glucose hypometabolism after 28 days on an oral dose of 1 g/kg/day of triheptanoin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrontal Lobe Hypometabolism
CountriesCanada
CollaboratorsUltragenyx Pharmaceutical Inc, Fonds de la Recherche en Santé du Québec

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 10, 2016
Enrollment StartApr 1, 2016
Primary CompletionAug 8, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.4 years ago

Interventions

POST Triheptanoindrug

The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.